NuCana PLC logo

NuCana PLC(NCNA)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$0.89
11/17/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for NCNA

11/17/2026: NCNA (1-star) is currently NOT-A-BUY. Pass it for now.

NuCana PLC is a clinical-stage biopharmaceutical stock focused on its proprietary ProTide technology platform to improve cancer treatment outcomes. The company's main operational strength lies in its promising mid-stage pipeline candidates, such as NUC-7738, which have demonstrated encouraging clinical activity in drug-resistant tumors. The primary investment opportunity centers on potential regulatory pathways and future pharmaceutical partnership prospects. However, the company faces substantial execution, financing, and high clinical attrition risks typical of pre-revenue biotechnology firms. NuCana suits speculative growth investors comfortable with high volatility, requiring close monitoring of clinical data readouts and cash burn metrics.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorMixed fitOffers potential high-growth exposure if clinical trials succeed, but carries high binary biotech risk.
Momentum investorStrong fit while signal remains positiveStock can experience sharp upward momentum around clinical data readouts and regulatory updates.
Value investorWeak fitThe company lacks commercial revenue, positive earnings, or traditional valuation support.
Dividend investorWeak fitNuCana does not pay dividends and retains all capital to fund clinical research.
Low-risk investorWeak fitHigh clinical development volatility and pre-commercial status create substantial risk exposure.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighClinical-stage biotechnology stocks frequently experience dramatic price swings based on trial data and capital updates.
Valuation riskHighWith no commercial revenue or earnings, valuation is speculative and tied entirely to pipeline potential.
Competition risk (oncology therapeutics)Medium / highIntense competition from well-funded biotechnology and pharmaceutical firms threatens future market adoption.
Business qualityMediumProprietary ProTide technology represents strong scientific quality, but lacks commercial commercialized proof.
Dividend incomeLow / noneNo dividend distributions are expected as capital is entirely reinvested into drug development.
Execution riskHighSuccess relies heavily on executing clinical trials smoothly and obtaining complex regulatory approvals.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 3.71M USD
Price to earnings Ratio -
1Y Target Price 104
Price to earnings Ratio -
1Y Target Price 104
Volume (30-day avg) 31.2K shares
Beta 2.44
52 Weeks Range 0.77 - 4.55
Updated Date 11/17/2026
52 Weeks Range 0.77 - 4.55
Updated Date 11/17/2026
Dividends yield (FY) -
Basic EPS (TTM) -

Sector & Industry Intelligence

Sector

Healthcare

Constructive
Sentiment
Strong Bullish
Momentum
BUY Breadth Improving
BUY participation
62.3%
Active BUY / eligible
66 / 106
30-Day BUY Count Change
+23
Market state
Strong Bullish

More qualifying stocks are receiving or maintaining BUY advisories, indicating improving market participation.

Industry

Biotechnology

BUY participation
43.6%
Active BUY / eligible
17 / 39
30-Day BUY Count Change
+10

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Steep Decline
PRICE PATH

Steep Decline

The stock price has dropped sharply with strong downward pressure.

Choppy
PRICE STABILITY

Choppy

The stock has experienced frequent reversals and pronounced short-term price swings.

Analysis of Past Performance

Type Stock
Historic Profit -25.82%
Avg. Invested days 7
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 2.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/17/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
NCNA receives a 2-star rating, reflecting soft or weak scores across the available pillars. The rating is constrained by weak unit economics, and weak price momentum.

Company Fundamentals

★★★★★
NCNA has moderate overall fundamentals (3 stars), with moderate financial health, moderate growth momentum, and moderate ownership. In FY2025 versus FY2024, growth and ownership metrics are mixed: negative earnings growth (-54.5%), soft cash generation (FCF margin 0.0%), slightly negative revenue growth (+0.0%).

Financial Health Rating

★★★★★
NCNA's financial health is supported by strong efficiency, including operating-expense and cost-of-revenue discipline (opex 0.0% of revenue). Profitability is weak (1 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
Free-cash-flow growth is NCNA's strongest growth driver at +60.5% FY2025 versus FY2024 (strong, 5 stars). By comparison, while revenue growth (+0.0%, slightly negative) and earnings growth (-54.5%, negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 1.9% (soft) and 103.5% of outstanding shares are publicly tradable (strong). Insider ownership is only 0.00%, which materially reduces the ownership score.

Top 5 Institutional Investors

StoneX Group Inc 1.13%
Citadel Advisors Llc 0.65%
HRT FINANCIAL LLC 0.41%
Glass Jacobson Investment Advisors LLC 0.36%
Rhumbline Advisers 0.11%

Unit Economics (Per $1K Revenue)

★★★★★
NCNA generates approximately $-0 of gross profit, $-0 of operating income, and $-0 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Weak margins explain the 1-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 3.83%

Quantitative Style Profile

★★★★★
NCNA has a liquid profile. Weak momentum is the primary drawback, while elevated volatility.

Style Classification

Quality Focused

Value-OrientedHigh VolatilitySmall / Mid Cap RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Commercial Product SalesNuCana currently has no approved commercialized products and generates zero product revenue.The company operates as a pre-revenue clinical enterprise dependent on future drug approvals or partnerships.
Strategic Collaborations and LicensingPotential upfront milestone payments, license fees, and royalties from future biopharmaceutical partnerships.Monetization will likely rely on codevelopment deals or licensing agreements with large pharmaceutical partners.

Valuation

Trailing PE -
Forward PE -
Enterprise Value -21.29M
Price to Sales(TTM) -
Enterprise Value -21.29M
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA 0.3
Shares Outstanding 4.16M
Shares Floating 4.31M
Shares Outstanding 4.16M
Shares Floating 4.31M
Percent Insiders -
Percent Institutions 1.94

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.